Evidence map›Paper›PMID 36296551›Full record

ArticleMolecules (Basel, Switzerland)2022

Design, Synthesis, Anticancer Activity and Molecular Docking of New 1,2,3-Triazole-Based Glycosides Bearing 1,3,4-Thiadiazolyl, Indolyl and Arylacetamide Scaffolds.

Hussein H Elganzory, Fahad M Alminderej, Mohamed N El-Bayaa, Hanem M Awad, Eman S Nossier, Wael A El-Sayed

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hussein H ElganzoryDepartment of Chemistry, College of Science, Qassim University, Buraidah 51452, Saudi Arabia.ORCID 0000-0002-9426-5434
Fahad M AlminderejDepartment of Chemistry, College of Science, Qassim University, Buraidah 51452, Saudi Arabia.ORCID 0000-0002-3649-0190
Mohamed N El-BayaaPhotochemistry Department, National Research Centre, Cairo 12622, Egypt.ORCID 0000-0003-3896-7025
Hanem M AwadTanning Materials and Leather Technology Department, National Research Centre, El-Behouth St, Dokki, Cairo 12622, Egypt.ORCID 0000-0002-3970-2371
Eman S NossierDepartment of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo 11754, Egypt.ORCID 0000-0001-6159-5333
Wael A El-SayedDepartment of Chemistry, College of Science, Qassim University, Buraidah 51452, Saudi Arabia.ORCID 0000-0002-8232-1830

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New 1,3,4-thiadiazole thioglycosides linked to a substituted arylidine system were synthesized via heterocyclization via click 1,3-dipolar cycloaddition. The click strategy was used for the synthesis of new 1,3,4-thiadiazole and 1,2,3-triazole hybrid glycoside-based indolyl systems as novel hybrid molecules by reacting azide derivatives with the corresponding acetylated glycosyl terminal acetylenes. The cytotoxic activities of the compounds were studied against HCT-116 (human colorectal carcinoma) and MCF-7 (human breast adenocarcinoma) cell lines using the MTT assay. The results showed that the key thiadiazolethione compounds, the triazole glycosides linked to p-methoxyarylidine derivatives and the free hydroxyl glycoside had potent activity comparable to the reference drug, doxorubicin, against MCF-7 human cancer cells. Docking simulation studies were performed to check the binding patterns of the synthesized compounds. Enzyme inhibition assay studies were also conducted for the epidermal growth factor receptor (EGFR), and the results explained the activity of a number of derivatives.

Indexed as

Antineoplastic AgentsThioglycosidesAlkynesAzidesCell ProliferationDoxorubicinDrug Screening Assays, AntitumorErbB ReceptorsGlycosidesHumansMCF-7 CellsMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipThiadiazolesTriazoles1,3,4-thiadiazoleAlkynesAntineoplastic AgentsAzidesDoxorubicinErbB ReceptorsGlycosidesThiadiazolesThioglycosidesTriazolesanticancerarylacetamideEGFRglycosidesHCT-116indoleMCF-7thiadiazoletriazole

Identifiers

PMID36296551
PMCPMC9611297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.